Review of clinical use of glucagon-like peptide-1 in the management of type 2 diabetes

摘要

Within the last decade, multiple new medications have been licensed for treating type 2 diabetes. These agents are vastly more expensive than their predecessors and usage requires review in practice. This retrospective case series reviewed 55 patients to assess the effect of glucagon-like peptide-1 (GLP-1) mimetics as add-on to existing antidiabetic therapy, including insulin, in clinical practice. The primary outcome measures were change in HbAk and weight. Analyses were also conducted to test the effect of: initial HbAk; concomitant insulin use; GLP-1 prescribed; and duration of diabetes on the change in HbAu and weight.